Maze Therapeutics (MAZE) Q3 2026 earnings review
Maze beats its kidney trial target, but research costs jump
Maze Therapeutics, a clinical-stage developer of oral drugs for kidney and metabolic diseases, finished recruiting for its lead kidney study while research costs jumped. Chief executive Jason Coloma said the Phase 2 HORIZON trial of MZE829 enrolled over 50 patients across three kidney disease groups, beating the 30-to-45 patient target. Research and development spending rose 60% from a year ago by our math to $40 million, while cash reserves ended September at $477 million.
| HORIZON Phase 2 enrollment | >50 patients target of 30–45 across 3 cohorts |
|---|---|
| Research and development expenses | $40.2M +60% from a year ago |
| Cash and marketable securities | $477.0M $494.9M last quarter |
| Cash runway outlook | Unchanged expected to fund operations into 2029 |
⚖️ Verdict: 🟢 Bullish
The story got better because over-enrolling the lead kidney trial gives Maze a larger dataset across all three patient subgroups before it designs its final-stage study. One caution: full HORIZON results will now arrive in early 2027 rather than late 2026, and quarterly operating expenses have climbed to $52 million before final-stage testing even starts.
The question now is whether MZE829 can lower urine protein in diabetic kidney patients as well as it did in the first 12 patients. Strong reductions across all three cohorts would support a broad final-stage trial, while weaker results in diabetic patients would narrow the drug's reach. Complete Phase 2 HORIZON data in early 2027 will settle it.
🐂 Bull Case
Lead Kidney Trial Beat Its Enrollment Target
Maze is testing MZE829, an oral drug for APOL1-mediated kidney disease (AMKD), a genetic form of kidney failure affecting over one million Americans. The company wants to show the pill works across three patient groups: those without diabetes, those with diabetes, and those with a scarring kidney condition called focal segmental glomerulosclerosis (FSGS).
Chief executive Jason Coloma said that completing enrollment in the Phase 2 HORIZON study with over 50 patients "exceeded our target enrollment of 10-15 patients per cohort". By our math, signing up more than 50 patients beats the 37.5-patient middle of that 30-to-45 target range by at least 33.3%.
A larger patient group matters because the earlier interim reading covered only 12 patients. Those 12 patients showed "clinically meaningful uACR reductions at 12 weeks among 12 efficacy-evaluable AMKD patients", referring to a drop in the urine protein ratio that measures kidney damage, so a 50-plus patient dataset gives regulators a wider test before final trials.
What to watch: the complete HORIZON data across all three cohorts in early 2027. Consistent protein reductions across diabetic and non-diabetic patients would support a broad final-stage trial in the first half of 2027.
Cash Reserves Cover More Than Nine Quarters
Clinical-stage drug developers without recurring product sales depend on their bank balances to survive multi-year testing. Maze ended September with $477.0 million in cash and marketable securities, up 24.2% from a year ago by our math after raising $150 million from stock sales and collecting a $20 million partnership payment from Shionogi in the spring.
The biotechnology company spent only $17.9 million of its cash pile during the third quarter by our math, down from $494.9 million in June. Even if quarterly cash outflows rise to match the $51.5 million operating loss, existing reserves cover 9.3 quarters by our math, backing up the company's plan to "fund operations into 2029 based on its current business plan".
What to watch: quarterly cash burn in early 2027 when Maze prepares the final-stage MZE829 study and starts the MZE782 kidney trial. Keeping cash outflows near $25 million to $35 million a quarter would preserve the 2029 buffer without new stock sales.
🐻 Bear Case
Research Spending Accelerated to 60% Growth
Running multiple mid-stage trials at once is lifting Maze's cost base much faster than earlier in the year. After growing roughly 24% from a year ago in both the first and second quarters by our math, research and development spending jumped 59.7% in the third quarter to $40.2 million.
- Research and development costs: $40.2 million, up 59.7% from a year ago and 15.1% from last quarter by our math
- General and administrative overhead: $11.3 million, up 45.3% from a year ago but down 13.7% from last quarter by our math
- Total operating expenses: $51.5 million, up 56.3% from a year ago by our math
- Net loss: $48.0 million, up 59.4% from $30.1 million a year ago by our math
The company said the higher spending came from the "progression of our MZE829 and MZE782 clinical development programs" along with employee pay and stock awards. Because Maze has not started its largest pivotal trial for MZE829 or its second Phase 2 trial for MZE782 yet, quarterly operating losses will climb further once those studies open.
What to watch: fourth-quarter research and development expenses when full-year results arrive. Another 15% quarterly jump would push annual operating expenses toward $200 million before pivotal testing even begins.
Two Timeline Windows Narrowed to Next Year
Coloma highlighted clinical momentum across both drug programs, yet the timetable for key milestones has shifted into 2027. Three months ago, Maze told investors to expect updated HORIZON kidney data in late 2026 or early 2027. In this quarter's release, the company dropped the late 2026 option and set the readout for early 2027.
That follows an earlier shift for its second drug, MZE782, an oral pill blocking the SLC6A19 transporter to treat phenylketonuria (PKU, an inherited metabolic disorder) and chronic kidney disease. Maze originally planned to start the MZE782 kidney disease trial in the second half of 2026, before moving the start date to the first half of 2027. That clusters four major clinical events into next year.
What to watch: regulatory feedback on the MZE829 pivotal trial design after the early 2027 HORIZON readout. Any request for extra dosing data from regulators would push the pivotal trial start past the first half of 2027.
👓 Other Themes
Two Industry Veterans Joined the Board
In August 2026, the drug developer appointed Dr. Paula Johnson and Dr. Sophie Kornowski to its board of directors. Maze said both new directors bring "decades of biopharmaceutical industry and clinical experience" as the group prepares for late-stage trials. They join BridgeBio chief executive Neil Kumar, who joined the board earlier this year.
💲 Other KPIs
Share count rose 33.0% from a year ago and 3.2% from the second quarter by our math, reflecting the $150 million stock and warrant offering completed in April 2026. The larger share base spread out the wider net loss, so loss per share rose 19.7% to $0.79 while total net loss rose 59.4% by our math.
Total liabilities nearly doubled from $42.2 million at the end of 2025, rising 96.9% over nine months and 5.7% from the second quarter by our math. The balance sheet increase came alongside $975 thousand of third-quarter interest expense, a cost line that did not exist a year ago.
Net other income grew 23.3% from $2.88 million a year ago by our math. Higher cash balances after the spring stock offering generated $4.52 million in interest income, which more than covered the new $975 thousand interest expense and trimmed the quarterly net loss by 6.9% by our math.
🔮 Guidance
Unchanged. Maze still expects its $477.0 million of cash and marketable securities to fund operations into 2029. The company extended this target from 2028 to 2029 in the first quarter after raising $150 million in equity and collecting a $20 million milestone from Shionogi, and it held the target despite higher third-quarter research spending.
Unchanged. The company narrowed the readout window for all three patient cohorts to early 2027, dropping the late 2026 portion of its prior timeframe. Over 50 patients are now enrolled, above the 30-to-45 target range, and the 12-week treatment window for the final patients pushes the full dataset into early next year.
Unchanged. The biopharmaceutical group still plans to start a final-stage pivotal trial for MZE829 in the first half of 2027, depending on feedback from regulators. Because full Phase 2 data now arrives in early 2027, management must complete regulatory meetings and trial setup within a few months to hit the first-half window.
Unchanged. Maze kept its plan to start a Phase 2 trial testing MZE782 for protein reduction in chronic kidney disease during the first half of 2027. The company had pushed this start date back from the second half of 2026 in the prior quarter, while enrollment in the companion CIPheR study for phenylketonuria continues for a 2027 readout.
❓ Key Questions
How many HORIZON patients are in each disease subgroup?
Maze enrolled more than 50 patients across three cohorts — kidney disease with diabetes, without diabetes, and with focal segmental glomerulosclerosis — above the 10-to-15 per cohort target. Knowing whether enrollment skewed toward one subgroup will show how much statistical weight each group carries in early 2027.
What drove the 97% jump in total liabilities this year?
Total liabilities rose from $42.2 million in December 2025 to $83.0 million in September 2026, and Maze recorded $975 thousand in quarterly interest expense. Because the release omits a debt and payables breakdown, investors cannot see how much is new debt versus clinical trial accruals.
When in 2027 will the CIPheR PKU trial report data?
Maze narrowed its HORIZON data timing to early 2027 and set two trial starts for the first half of 2027, but left the Phase 2 CIPheR readout in phenylketonuria as a full-year 2027 window. Enrollment pacing in CIPheR will determine whether data arrives in the first or second half.
What are the next Shionogi milestone triggers for MZE001?
Maze recognized $20 million in license revenue in the first quarter when partner Shionogi dosed the first Pompe disease patient, and remains eligible for up to $255 million in development milestones. Management did not say which clinical event triggers the next cash payment.